Therapeutic effect Of D-004, a lipid extract from roystonea regia fruits, on prostate hyperplasia induced in rats

Drugs under Experimental and Clinical Research

Volumn 31, Issue 5-6, 2005, Pages 193-197

  Carbajal, D ^a   Molina, V ^a   Mas R ^a,b   Arruzazabala, M L ^a  

^a Center for Natural Products of the National Center for Scientific Research   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

D 004; LIPID; PALM OIL; PLANT EXTRACT; PROSEREN; SABAL EXTRACT; SOYBEAN OIL; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BENIGN TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FRUIT; GROWTH INHIBITION; MALE; NONHUMAN; PHYTOTHERAPY; PROSTATE HYPERTROPHY; RAT; ROYSTONEA REGIA; TREATMENT OUTCOME; TUMOR GROWTH;

ANIMALS; ARECACEAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUIT; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RATS; SERENOA; TESTOSTERONE;

EID: 30144439124     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lamb J.C., English H.L., Levandoski P., et al. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: Role for testosterone in the androgenic response. Endocrinology, 130, 685, 1992.
2. Carson C., Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology, 61(Suppl. 1), 2, 2003.
3. Bartsch G., Rittmaster R.S., Klocker H. Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe A, 41, 412, 2002.
4. Boyle P., Napalkov P. Epidemiology of benign prostatic hyperplasia: Current perspectives. Eur. Urol., 29, 7, 1996.
5. Hieble J.P., Ruffolo R.F. Jr. Pharmacotherapy of benign prostatic hypertrophy with α1-adrenoceptor antagonists. Pharmacol. Rev. Comm., 8, 251, 1996.
6. Joseph E., Oesterling M.D. Benign prostatic hyperplasia: Medical and minimally invasive treatment options. New Engl. J. Med., 332, 99, 1995.
7. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients. Prostate, 29, 231, 1996.
8. Van Coppenolle F., Le Bourhis X., Carpentier F., et al. Pharmacological effects of the lipidosterolic extract of Serenoa repens (Permixon) on rat prostate hyperplasia induced by hyperprolactinemia: Comparison with finasteride. Prostate, 43, 49, 2000.
9. Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review. Urology, 48, 12, 1996.
10. Paubert-Braquet M., Mencia J.M., Cousse H., Braquet P. Effect of the lipidic lipidosterolic extract of Serenoa repens (Permixon) on the ionophore A23187-stimulated production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils. Prostagl. Leukotr. Essen. Fatty Acids, 57, 299, 1997.
11. Briley M., Carilla E., Roger A. Inhibitory effect of Permixon on testosterone 5α-reductase activity of the rat ventral prostate. Br. J. Pharmacol., 83(Suppl), 401, 1984.
12. Marks L.S., Hess D.L., Dorey F.J., et al. Tissue effects of Saw palmetto and finasteride: Use of biopsy cores for in situ quantification of prostatic androgens. Urology, 57, 999, 2001.
13. Marks L.S. Partin A.W., Epstein J.I., et al. Effects of a Saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J. Urol., 163, 1451, 2000.
14. Plosker G.L., Brodgen R.N. Serenoa repens (Permixon): A review of its pharmacological and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging, 9, 379, 1996.
15. Wilt T.J., Ishani A., Stark G., et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia: A systematic review. JAMA, 280, 1604, 1998.
16. Gordon A.E., Shaughnessy A.F. Saw palmetto for prostate disorders. Am. Fam. Physician, 67, 1281, 2003.
17. Goepel M., Hecker U., Krege S., et al. Saw palmetto extracts potently and non-competitively inhibit human alpha 1 adrenoceptors in vitro. Prostate, 38, 208, 1999.
18. Marks E. Effects of Saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J. Urol., 163, 1451, 2000.
19. Carraro J.C., Raynaud J.P., Koch G., et al. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients. Prostate, 29, 231, 1996.
20. Paubert-Braquet M., Richardson F.O., Servent-Saez N., et al. Effect of Serenoa repens extract (Permixon) on estradiol/testosterone-induced experimental prostate enlargement in the rat. Pharmacol. Res., 34, 171, 1996.
21. Bombardelli E., Morazzoni P., Small J.K. Serenoa repens (Bartram). Fitoterapia, 68, 99, 1997.
22. Arruzazabala M.L., Carbajal D., Más R., et al. Preventive effects of D-004, a lipid extract from Cuban royal palm (Rostonea regia) fruits, on prostate hyperplasia induced with testosterone on intact and castrated rodents. Drugs Exptl. Clin. Res., 30, 227, 2004.
23. Carbajal D., Arruzazabala M.L., Más R., et al. Effects of D-004, a lipid extract from Cuban royal palm fruit, on inhibiting prostatic hyperplasia induced with testosterone or dihydrotestosterone in a rat model: A randomized, controlled study. Curr. Ther. Res., 65, 505, 2004.